• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BTG to buy PneumRx for up to $475m

BTG to buy PneumRx for up to $475m

December 4, 2014 By MassDevice Contributors Network

BTG to buy PneumRx for up to $475m

(Reuters) — BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a California firm that has developed a device to prop open airways.

The British company said today that it would pay an initial $230 million and up to $245 million in performance-related milestones to acquire privately-owned PneumRx.

The U.S. firm’s flagship product is the RePneu Coil for advanced emphysema, which tethers small airways open to prevent their collapse.

BTG said the business had potential annual sales of more than $250 million and was expected to boost earnings from the 4th year onwards. The purchase will be funded in part by a £150 million ($235 million) share placing.

The RePneu Coil is already approved and on the market in Europe. It is still awaiting a green light in the U.S., which BTG said it hoped to get by the end of 2016.

The acquisition underscores the growth ambitions of BTG, which has emerged over the years from the former state-owned British Technology Group as a company focused on specialty pharmaceuticals and interventional medicine.

CEO Louise Makin said the addition of PneumRx would boost growth prospects significantly, with the interventional medicine business now expected to generate annual sales of more than $1.25 billion by the beginning of the next decade.

Currently, BTG’s interventional medicine business has annual sales of $150 million, which will rise to $175 million after the PneumRx deal closes early next year.

Makin said BTG did not need to make further acquisitions but the company was on the lookout for similar opportunities in other fast-growing areas.

"If there was something that would fit either in specialty pharma or an area of interventional medicine, then we would go through the same thought process," she said in an interview. "But our strategy does not require us to do more M&A."

Adding PneumRx will see BTG entering a third area of interventional medicine – pulmonology – in addition to oncology and vascular medicine.

BTG’s interventional cancer business consists of high-tech beads that release medicine or radiation to fight tumors, while its vascular unit includes Varithena, a recently launched foam that is injected into blood vessels to treat varicose veins.

Its specialty pharmaceuticals operation is famous for CroFab snake antivenom.

Filed Under: Mergers & Acquisitions, News Well Tagged With: BTG, PneumRx Inc., Pulmonary

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy